Center for Orthopaedic Outcomes Research, The Steadman Philippon Research Institute, Vail, CO, USA.
Center for Orthopaedic Outcomes Research, The Steadman Philippon Research Institute, Vail, CO, USA; School of Medicine, Oregon Health & Science University, Portland, OR, USA.
Clin Sports Med. 2019 Jan;38(1):163-168. doi: 10.1016/j.csm.2018.08.008.
The decision to incorporate ortho-biologics into a clinical practice will ultimately depend on physicians' preferences and the resources available to their practice. It is important to emphasize that different biologics are used for different pathologies/injuries and in different settings, such as the operating room or in the office. Physicians thinking about using biologics in their practices should consider the time commitment required to learn and use the technique, insurance coverage, and informed consent. The decision to treat patients with ortho-biologics should be a shared decision based on current literature, previous treatment regimen, and patients' goals.
是否将矫形生物制剂纳入临床实践,最终将取决于医生的偏好和其所在医疗实践的资源情况。需要强调的是,不同的生物制剂针对不同的病理/损伤,在不同的环境下使用,例如手术室或办公室。考虑在临床实践中使用生物制剂的医生应考虑学习和使用该技术所需的时间承诺、保险覆盖范围和知情同意。使用矫形生物制剂治疗患者的决策应该是基于当前文献、之前的治疗方案和患者目标的共同决策。